| Patient-paired sample congruence between 2 commercial liquid biopsy tests G Torga, KJ Pienta JAMA oncology 4 (6), 868-870, 2018 | 192 | 2018 |
| Glycolysis is the primary bioenergetic pathway for cell motility and cytoskeletal remodeling in human prostate and breast cancer cells T Shiraishi, JE Verdone, J Huang, UD Kahlert, JR Hernandez, G Torga, ... Oncotarget 6 (1), 130, 2015 | 181 | 2015 |
| Polyploid giant cancer cells: Unrecognized actuators of tumorigenesis, metastasis, and resistance SR Amend, G Torga, KC Lin, LG Kostecka, A de Marzo, RH Austin, ... The Prostate 79 (13), 1489-1497, 2019 | 139 | 2019 |
| The role of heterogeneous environment and docetaxel gradient in the emergence of polyploid, mesenchymal and resistant prostate cancer cells KC Lin, G Torga, Y Sun, R Axelrod, KJ Pienta, JC Sturm, RH Austin Clinical & experimental metastasis 36, 97-108, 2019 | 59 | 2019 |
| HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer D Johng, G Torga, CM Ewing, K Jin, JD Norris, DP McDonnell, WB Isaacs The Prostate 79 (4), 414-424, 2019 | 47 | 2019 |
| AXL is a putative tumor suppressor and dormancy regulator in prostate cancer HD Axelrod, KC Valkenburg, SR Amend, JL Hicks, P Parsana, G Torga, ... Molecular Cancer Research 17 (2), 356-369, 2019 | 46 | 2019 |
| Recent progress in the systemic treatment of advanced/metastatic cholangiocarcinoma RM Fostea, E Fontana, G Torga, HT Arkenau Cancers 12 (9), 2599, 2020 | 37 | 2020 |
| Large expert-curated database for benchmarking document similarity detection in biomedical literature search P Brown, AC Tan, MA El-Esawi, T Liehr, O Blanck, DP Gladue, ... Database 2019, 2019 | 34 | 2019 |
| Alternative CD44 splicing identifies epithelial prostate cancer cells from the mesenchymal counterparts JR Hernandez, JJ Kim, JE Verdone, X Liu, G Torga, KJ Pienta, ... Medical Oncology 32, 1-9, 2015 | 28 | 2015 |
| The presence of androgen receptor elements regulates ZEB1 expression in the absence of androgen receptor SM Mooney, P Parsana, JR Hernandez, X Liu, JE Verdone, G Torga, ... Journal of cellular biochemistry 116 (1), 115-123, 2015 | 20 | 2015 |
| High KIFC1 expression is associated with poor prognosis in prostate cancer LG Kostecka, A Olseen, KC Kang, G Torga, KJ Pienta, SR Amend Medical Oncology 38, 1-9, 2021 | 19 | 2021 |
| Epithelial and mesenchymal prostate cancer cell population dynamics on a complex drug landscape KC Lin, G Torga, A Wu, JD Rabinowitz, WJ Murray, JC Sturm, KJ Pienta, ... Convergent science physical oncology 3 (4), 045001, 2017 | 13 | 2017 |
| Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress tolerance D Tarantino, C Walker, D Weekes, H Pemberton, K Davidson, G Torga, ... Oncogene 41 (32), 3969-3977, 2022 | 11 | 2022 |
| Cancer dormancy and criticality from a game theory perspective A Wu, D Liao, V Kirilin, KC Lin, G Torga, J Qu, L Liu, JC Sturm, K Pienta, ... Cancer convergence 2, 1-8, 2018 | 11 | 2018 |
| An in vitro tumor swamp model of heterogeneous cellular and chemotherapeutic landscapes KC Lin, Y Sun, G Torga, P Sherpa, Y Zhao, J Qu, SR Amend, KJ Pienta, ... Lab on a Chip 20 (14), 2453-2464, 2020 | 10 | 2020 |
| Longitudinal stability of molecular alterations and drug response profiles in tumor spheroid cell lines enables reproducible analyses AC Nickel, D Picard, N Qin, M Wolter, K Kaulich, M Hewera, D Pauck, ... Biomedicine & Pharmacotherapy 144, 112278, 2021 | 8 | 2021 |
| Ten unanswered questions in cancer:“If this is true, what does it imply”? SR Amend, AE de Groot, G Torga, HD Axelrod, DK Reyes, KC Valkenburg, ... American journal of clinical and experimental urology 6 (2), 26, 2018 | 6 | 2018 |
| Uptake of prostate-specific membrane antigen-targeted 18F-DCFPyL in avascular necrosis of the femoral head G Torga, Y Yin, MG Pomper, KJ Pienta, MA Gorin, SP Rowe World Journal of Nuclear Medicine 18 (04), 416-419, 2019 | 5 | 2019 |
| Rare renal incidentaloma in pregnancy: An unusual primitive neuroectodermal tumor presentation G Torga, W Barrow, M Han Urology Case Reports 3 (2), 12-14, 2015 | 5 | 2015 |
| BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: A case series SR Butt, A Mejias, C Morelli, G Torga, M Happe, A Patrikidou, HT Arkenau Cancer Chemotherapy and Pharmacology 87, 437-441, 2021 | 4 | 2021 |
